288384-91-8

Usage

Chemical structure

Chlorinated derivative of benzimidazole
The compound is derived from benzimidazole, a heterocyclic compound, by substituting a chlorine atom in the 2 position of the benzimidazole ring.

Bicyclic structure

Consisting of two fused rings
The benzimidazole ring system is composed of two fused rings, which contribute to its unique chemical and physical properties.

Presence of functional groups

Hydroxyl (-OH) and chloro (-Cl) groups
The compound contains a hydroxyl group at the 5 position and a chlorine atom at the 2 position, which influence its reactivity and potential applications.

Applications

Building block in the synthesis of pharmaceutical drugs, pesticides, and other organic compounds
Due to its unique structure, the compound is used as a starting material for the synthesis of various chemical and pharmaceutical products.

Medicinal chemistry research

Potential biological activity and therapeutic applications
The compound's structural characteristics may provide it with biological activity, making it a candidate for further research in the development of new drugs and therapies.

Further studies needed

To fully understand and exploit its potential uses
More research is required to determine the compound's full range of applications and to optimize its synthesis and use in various industries.

CAS Registry Number

9CI
The compound is registered with the Chemical Abstracts Service (CAS) under the unique identifier 9CI, which helps in its identification and tracking in scientific literature and databases.

Upstream product

• 15965-54-5 2-chloro-5-methoxy-1H-1,3-benzimidazole 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.